Enveric Biosciences
ENVB
10 hedge funds and large institutions have $636K invested in Enveric Biosciences in 2023 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 1 closing their positions.
23% more capital invested
Capital invested by funds: $518K → $636K (+$117K)
0.06% more ownership
Funds ownership: 0.06% → 0.12% (+0.06%)
0% more funds holding
Funds holding: 10 → 10 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$466K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$5.22K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$307 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
-$8.6K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$7.37K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$614 |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
-$307 |
| 5 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
-$129 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AC
1
Armistice Capital
New York
| $355K | +$466K | +1,517 | New |
|
|
AI
2
AdvisorShares Investments
Bethesda,
Maryland
| $184K | -$8.6K | -28 | -3% |
|
3
BlackRock
New York
| $38.5K | – | – | – |
|
|
4
Vanguard Group
Malvern,
Pennsylvania
| $23.7K | +$307 | +1 | +1% |
|
5
Geode Capital Management
Boston,
Massachusetts
| $17.1K | – | – | – |
|
|
TRCT
6
Tower Research Capital (TRC)
New York
| $16.5K | +$5.22K | +17 | +32% |
|
7
Group One Trading
Chicago,
Illinois
| $355 | – | – | – |
|
|
8
Osaic Holdings
Scottsdale,
Arizona
| $195 | -$307 | -1 | -50% |
|
9
Bank of America
Charlotte,
North Carolina
| $130 | – | – | – |
|
10
National Bank of Canada
Montreal,
Quebec, Canada
| $88 | – | – | – |
|
11
Wells Fargo
San Francisco,
California
| $43 | – | – | – |
|
|
12
UBS Group
Zurich,
Switzerland
| $13 | -$614 | -2 | Closed |
|
|
OP
13
ORG Partners
Roanoke,
Indiana
| $13 | – | – | – |
|
14
Morgan Stanley
New York
| $2 | – | – | – |
|
|
15
Acadian Asset Management
Boston,
Massachusetts
| – | -$7.37K | -24 | -96% |
|
|
16
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
| – | -$129 | – | – |
|
ENVB Hedge Fund Activity: Q4 2023 in Review
10 of the 6,863 institutional investors tracked by Wall St. Rank reported a position in Enveric Biosciences (ENVB) for Q4 2023, worth a combined $636K — up 23% from $518K a quarter earlier.
Fund positioning in ENVB was balanced in Q4 2023: 1 fund opened new positions, 1 closed out, 2 added to existing stakes and 3 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $466K. The largest seller was AdvisorShares Investments, cutting an estimated $8.6K.
- 10 institutional investors held Enveric Biosciences (ENVB) as of Q4 2023, unchanged from Q3 2023.
- Funds reported $636K of Enveric Biosciences stock for Q4 2023, up 23% quarter-over-quarter.
- 1 fund opened new Enveric Biosciences positions in Q4 2023 and 1 closed out, a net change of 0 holders.
- The largest Enveric Biosciences buyer in Q4 2023 was Armistice Capital, an estimated $466K added.
- The largest Enveric Biosciences seller in Q4 2023 was AdvisorShares Investments, an estimated $8.6K sold.
Based on aggregated 13F filings for Q4 2023.